Michael F. Giordano - 03 Mar 2026 Form 4 Insider Report for RAPT Therapeutics, Inc. (RAPT)

Reporting relationship: Director
Issuer ticker: RAPT
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 09:01:13 UTC
Prior SEC filing: 02 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Rodney Young, Attorney-in-Fact

Key filing fact

Michael F. Giordano filed Form 4 for RAPT Therapeutics, Inc. (RAPT) on 05 Mar 2026.

Key facts

This page summarizes Michael F. Giordano's Form 4 filing for RAPT Therapeutics, Inc. (RAPT).
10 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 05 Mar 2026, 09:01.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001733915 Primary reporting owner

Giordano Michael F

Relationship: Director
Address: C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO
Signature: /s/ Rodney Young, Attorney-in-Fact
Signature date: 05 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -4,956
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -824
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 824
Exercise price: $49.44
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -799
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 799
Exercise price: $96.00
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -938
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 938
Exercise price: $226.16
Footnotes: F2, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -938
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 938
Exercise price: $154.40
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -402
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 402
Exercise price: $175.92
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,063
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,063
Exercise price: $109.12
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,618
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,618
Exercise price: $167.44
Footnotes: F2, F4, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -4,561
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,561
Exercise price: $37.04
Footnotes: F2, F5, F6

RAPT transaction Derivative

Director Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -32,229
Change %: -100%
Price
Shares after: 0
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,229
Exercise price: $7.44
Footnotes: F2, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael F. Giordano is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

Footnote F2

The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the "Merger Agreement") with GlaxoSmithKline LLC, a Delaware limited liability company ("Parent"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").

Footnote F3

Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement.

Footnote F4

This Form 4 reports securities transacted pursuant to the Merger Agreement.

Footnote F5

The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025.

Footnote F6

Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration.